Jinling Pharmaceutical Company Limited (SHE:000919)
China flag China · Delayed Price · Currency is CNY
6.69
-0.09 (-1.33%)
May 20, 2026, 3:04 PM CST

SHE:000919 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
3,1303,1723,2563,1642,6492,789
Other Revenue
25.7725.7725.0229.5222.1519.62
3,1563,1973,2813,1942,6712,809
Revenue Growth (YoY)
-2.76%-2.56%2.74%19.58%-4.91%12.18%
Cost of Revenue
2,4822,5312,6762,5572,1422,181
Gross Profit
674.45665.96605.17637.06528.55628.17
Selling, General & Admin
510.13507.86446.73460.88383.48384.3
Research & Development
114.84110.14110.6979.1474.1757.01
Other Operating Expenses
22.282320.681318.2119.28
Operating Expenses
645.24641579.86556.22477.52458.93
Operating Income
29.2124.9625.3180.8451.03169.24
Interest Expense
-5.53-5.21-2.2-1.3-0.26-0.29
Interest & Investment Income
41.7249.3863.9158.1434.9846.4
Currency Exchange Gain (Loss)
0.010.010.040.020.08-0
Other Non Operating Income (Expenses)
8.098.41.73-1.07-1.45-1.42
EBT Excluding Unusual Items
73.5177.5488.8136.6384.38213.92
Impairment of Goodwill
-18.05-18.05-86.3---45.97
Gain (Loss) on Sale of Investments
3.74-0.1114.39-0.96-27.14-29.95
Gain (Loss) on Sale of Assets
4.53-0.3921.34-0.5661.8351.98
Asset Writedown
-0.91-0.91-10.01-0.15--1.56
Other Unusual Items
7.17.111.813.48.716.38
Pretax Income
69.9365.1940.01148.36127.77194.81
Income Tax Expense
14.1713.922.0519.613.941.88
Earnings From Continuing Operations
55.7651.2917.95128.76113.87152.94
Minority Interest in Earnings
3.182.6222.46-22.57-8.58-32.31
Net Income
58.9453.9140.41106.19105.28120.63
Net Income to Common
58.9453.9140.41106.19105.28120.63
Net Income Growth
222.63%33.42%-61.95%0.87%-12.72%85.19%
Shares Outstanding (Basic)
622622593504504504
Shares Outstanding (Diluted)
622622593504504504
Shares Change (YoY)
0.41%4.95%17.56%0.01%-0.02%-0.01%
EPS (Basic)
0.090.090.070.210.210.24
EPS (Diluted)
0.090.090.070.210.210.24
EPS Growth
221.33%27.13%-67.63%0.86%-12.70%85.22%
Free Cash Flow
143.7916.34-47.44-25.85-49.05129.26
Free Cash Flow Per Share
0.230.03-0.08-0.05-0.100.26
Dividend Per Share
0.1000.1000.1000.1000.1000.100
Gross Margin
21.37%20.83%18.44%19.95%19.79%22.36%
Operating Margin
0.93%0.78%0.77%2.53%1.91%6.02%
Profit Margin
1.87%1.69%1.23%3.33%3.94%4.29%
Free Cash Flow Margin
4.56%0.51%-1.45%-0.81%-1.84%4.60%
EBITDA
169.75168.35180.06229.81173.57291.14
EBITDA Margin
5.38%5.27%5.49%7.20%6.50%10.37%
D&A For EBITDA
140.54143.38154.75148.97122.54121.9
EBIT
29.2124.9625.3180.8451.03169.24
EBIT Margin
0.93%0.78%0.77%2.53%1.91%6.02%
Effective Tax Rate
20.26%21.32%55.12%13.21%10.88%21.50%
Revenue as Reported
3,1563,1973,2813,1942,6712,809
Source: S&P Global Market Intelligence. Standard template. Financial Sources.